Who is sponsoring NCT03620513?

NCT03620513 is sponsored by Lumbini Medical College.

What drugs are being tested in NCT03620513?

Interventions in NCT03620513: Decongestant (oxymetazoline 0.05%), Anesthesia (Lidocaine 15%), Decongestants and Anesthesia (oxymetazoline and lidocaine), Normal saline.

What condition does NCT03620513 study?

NCT03620513 studies Throat Disorder.

Is NCT03620513 still recruiting?

NCT03620513 is currently completed. Last updated 9 March 2020.

Last reviewed 2020-03-09 · How we verify

NCT03620513

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pretreatment to Reduce Pain and Discomfort During Fiberoptic Nasal Pharyngoscopy and Laryngoscopy

Completed Phase 4 Last updated 9 March 2020

What this trial tests

Phase 4 trial testing Decongestant (oxymetazoline 0.05%) in Throat Disorder in 160 participants. Completed in 16 February 2019.

Timeline

1 September 2018

Primary endpoint
16 January 2019

16 February 2019

Quick facts

Lead sponsor	Lumbini Medical College
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	160
Start date	1 September 2018
Primary completion	16 January 2019
Estimated completion	16 February 2019
Sites	1 location across Nepal

Drugs / interventions tested

Decongestant (oxymetazoline 0.05%) — full drug profile →
Anesthesia (Lidocaine 15%) — full drug profile →
Decongestants and Anesthesia (oxymetazoline and lidocaine) — full drug profile →
Normal saline

Conditions studied

Throat Disorder — all drugs for Throat Disorder →

Sponsor

Lumbini Medical College

Who can join

18 and older, any sex, with Throat Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fiberoptic laryngoscopy (FOL) is one of the most common procedure done in an Ear Nose Throat (ENT) clinic. Topical anesthesia or decongestant or both have been used to improve patient comfort level during the procedure. Recently, role of these agents has been questioned. The investigators would like to study whether topical anesthesia or decongestant or their combination provide any benefit to the patients undergoing FOL.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Lumbini Medical College trials

Trials by the same sponsor.

NCT03590912 — Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion · Phase 4 · completed
NCT03427502 — Anterior Ethmoidal Nerve Block in Prevention of Postoperative Agitation · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03620513 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lumbini Medical College
Last refreshed: 9 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03620513.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing